GO:0006952 | defense response | 40.82% (40/98) | 1.6 | 0.0 | 0.0 |
GO:0044419 | biological process involved in interspecies interaction between organisms | 41.84% (41/98) | 1.44 | 0.0 | 0.0 |
GO:0051707 | response to other organism | 40.82% (40/98) | 1.45 | 0.0 | 0.0 |
GO:0043207 | response to external biotic stimulus | 41.84% (41/98) | 1.38 | 0.0 | 0.0 |
GO:0016799 | hydrolase activity, hydrolyzing N-glycosyl compounds | 9.18% (9/98) | 4.18 | 0.0 | 0.0 |
GO:0003953 | NAD+ nucleosidase activity | 8.16% (8/98) | 4.58 | 0.0 | 0.0 |
GO:0009607 | response to biotic stimulus | 41.84% (41/98) | 1.36 | 0.0 | 0.0 |
GO:0019362 | pyridine nucleotide metabolic process | 8.16% (8/98) | 4.41 | 0.0 | 1e-06 |
GO:0046496 | nicotinamide nucleotide metabolic process | 8.16% (8/98) | 4.43 | 0.0 | 1e-06 |
GO:0006968 | cellular defense response | 6.12% (6/98) | 5.34 | 0.0 | 1e-06 |
GO:0072524 | pyridine-containing compound metabolic process | 8.16% (8/98) | 4.21 | 0.0 | 2e-06 |
GO:0009605 | response to external stimulus | 44.9% (44/98) | 1.17 | 0.0 | 2e-06 |
GO:0019364 | pyridine nucleotide catabolic process | 6.12% (6/98) | 5.0 | 0.0 | 3e-06 |
GO:0019677 | NAD catabolic process | 6.12% (6/98) | 5.0 | 0.0 | 3e-06 |
GO:0050135 | NAD(P)+ nucleosidase activity | 6.12% (6/98) | 4.96 | 0.0 | 4e-06 |
GO:0072526 | pyridine-containing compound catabolic process | 6.12% (6/98) | 4.85 | 0.0 | 6e-06 |
GO:0098542 | defense response to other organism | 30.61% (30/98) | 1.46 | 0.0 | 1.2e-05 |
GO:0010267 | ta-siRNA processing | 5.1% (5/98) | 4.92 | 1e-06 | 5.1e-05 |
GO:0016441 | post-transcriptional gene silencing | 6.12% (6/98) | 4.15 | 1e-06 | 8.3e-05 |
GO:0009166 | nucleotide catabolic process | 6.12% (6/98) | 4.1 | 2e-06 | 9.8e-05 |
GO:1901292 | nucleoside phosphate catabolic process | 6.12% (6/98) | 4.01 | 2e-06 | 0.000134 |
GO:0030422 | siRNA processing | 5.1% (5/98) | 4.49 | 3e-06 | 0.000184 |
GO:0007591 | molting cycle, chitin-based cuticle | 2.04% (2/98) | 8.64 | 6e-06 | 0.000308 |
GO:0008860 | ferredoxin-NAD+ reductase activity | 2.04% (2/98) | 8.64 | 6e-06 | 0.000308 |
GO:0015039 | NADPH-adrenodoxin reductase activity | 2.04% (2/98) | 8.64 | 6e-06 | 0.000308 |
GO:0004521 | endoribonuclease activity | 5.1% (5/98) | 4.29 | 6e-06 | 0.000344 |
GO:0010942 | positive regulation of cell death | 9.18% (9/98) | 2.74 | 9e-06 | 0.000414 |
GO:0009620 | response to fungus | 18.37% (18/98) | 1.68 | 1e-05 | 0.000435 |
GO:0016798 | hydrolase activity, acting on glycosyl bonds | 10.2% (10/98) | 2.51 | 1.1e-05 | 0.000439 |
GO:0009117 | nucleotide metabolic process | 10.2% (10/98) | 2.52 | 1e-05 | 0.000446 |
GO:0034655 | nucleobase-containing compound catabolic process | 8.16% (8/98) | 2.95 | 1e-05 | 0.000459 |
GO:0006753 | nucleoside phosphate metabolic process | 10.2% (10/98) | 2.5 | 1.2e-05 | 0.000469 |
GO:0035073 | pupariation | 2.04% (2/98) | 8.05 | 1.9e-05 | 0.000727 |
GO:0043068 | positive regulation of programmed cell death | 8.16% (8/98) | 2.81 | 2e-05 | 0.000757 |
GO:0006793 | phosphorus metabolic process | 22.45% (22/98) | 1.39 | 2.3e-05 | 0.000836 |
GO:0051214 | RNAi-mediated antiviral immunity against RNA virus | 3.06% (3/98) | 5.77 | 2.3e-05 | 0.000837 |
GO:0055086 | nucleobase-containing small molecule metabolic process | 10.2% (10/98) | 2.3 | 3.8e-05 | 0.001332 |
GO:0006950 | response to stress | 46.94% (46/98) | 0.75 | 5e-05 | 0.001707 |
GO:0070918 | small regulatory ncRNA processing | 5.1% (5/98) | 3.64 | 5.4e-05 | 0.001781 |
GO:0006796 | phosphate-containing compound metabolic process | 21.43% (21/98) | 1.35 | 5.7e-05 | 0.001843 |
GO:0004540 | ribonuclease activity | 5.1% (5/98) | 3.6 | 6.2e-05 | 0.001869 |
GO:0102387 | 2-phenylethanol acetyltransferase activity | 2.04% (2/98) | 7.32 | 6.2e-05 | 0.001899 |
GO:0102720 | acetyl-coenzyme A:acetyl alcohol acetyltransferase activity | 2.04% (2/98) | 7.32 | 6.2e-05 | 0.001899 |
GO:0035196 | miRNA processing | 4.08% (4/98) | 4.2 | 7e-05 | 0.001932 |
GO:0044270 | cellular nitrogen compound catabolic process | 8.16% (8/98) | 2.56 | 6.8e-05 | 0.001936 |
GO:0046700 | heterocycle catabolic process | 8.16% (8/98) | 2.55 | 6.9e-05 | 0.001943 |
GO:0046434 | organophosphate catabolic process | 6.12% (6/98) | 3.13 | 6.8e-05 | 0.001977 |
GO:0050896 | response to stimulus | 58.16% (57/98) | 0.59 | 7.6e-05 | 0.002029 |
GO:0010941 | regulation of cell death | 12.24% (12/98) | 1.86 | 0.000113 | 0.00297 |
GO:0016787 | hydrolase activity | 23.47% (23/98) | 1.2 | 0.000116 | 0.002989 |
GO:0035194 | post-transcriptional gene silencing by RNA | 4.08% (4/98) | 3.86 | 0.000175 | 0.004024 |
GO:0004324 | ferredoxin-NADP+ reductase activity | 2.04% (2/98) | 6.64 | 0.000173 | 0.00404 |
GO:0007552 | metamorphosis | 2.04% (2/98) | 6.64 | 0.000173 | 0.00404 |
GO:0008937 | ferredoxin-NAD(P) reductase activity | 2.04% (2/98) | 6.64 | 0.000173 | 0.00404 |
GO:0003197 | endocardial cushion development | 2.04% (2/98) | 6.64 | 0.000173 | 0.00404 |
GO:1902811 | positive regulation of skeletal muscle fiber differentiation | 2.04% (2/98) | 6.64 | 0.000173 | 0.00404 |
GO:0010599 | lsiRNA processing | 2.04% (2/98) | 6.47 | 0.000221 | 0.004834 |
GO:0003228 | atrial cardiac muscle tissue development | 2.04% (2/98) | 6.47 | 0.000221 | 0.004834 |
GO:0006978 | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | 2.04% (2/98) | 6.47 | 0.000221 | 0.004834 |
GO:0010216 | maintenance of DNA methylation | 3.06% (3/98) | 4.64 | 0.000244 | 0.005228 |
GO:0016731 | oxidoreductase activity, acting on iron-sulfur proteins as donors, NAD or NADP as acceptor | 2.04% (2/98) | 6.32 | 0.000276 | 0.005234 |
GO:0042772 | DNA damage response, signal transduction resulting in transcription | 2.04% (2/98) | 6.32 | 0.000276 | 0.005234 |
GO:0045663 | positive regulation of myoblast differentiation | 2.04% (2/98) | 6.32 | 0.000276 | 0.005234 |
GO:1902809 | regulation of skeletal muscle fiber differentiation | 2.04% (2/98) | 6.32 | 0.000276 | 0.005234 |
GO:2000766 | negative regulation of cytoplasmic translation | 2.04% (2/98) | 6.32 | 0.000276 | 0.005234 |
GO:2001016 | positive regulation of skeletal muscle cell differentiation | 2.04% (2/98) | 6.32 | 0.000276 | 0.005234 |
GO:0008081 | phosphoric diester hydrolase activity | 4.08% (4/98) | 3.71 | 0.00026 | 0.005493 |
GO:0016891 | endoribonuclease activity, producing 5'-phosphomonoesters | 3.06% (3/98) | 4.58 | 0.000275 | 0.005712 |
GO:0009616 | RNAi-mediated antiviral immune response | 3.06% (3/98) | 4.52 | 0.000309 | 0.005766 |
GO:0010831 | positive regulation of myotube differentiation | 2.04% (2/98) | 6.18 | 0.000337 | 0.005949 |
GO:1905868 | regulation of 3'-UTR-mediated mRNA stabilization | 2.04% (2/98) | 6.18 | 0.000337 | 0.005949 |
GO:1905870 | positive regulation of 3'-UTR-mediated mRNA stabilization | 2.04% (2/98) | 6.18 | 0.000337 | 0.005949 |
GO:1990715 | mRNA CDS binding | 2.04% (2/98) | 6.18 | 0.000337 | 0.005949 |
GO:0061980 | regulatory RNA binding | 3.06% (3/98) | 4.44 | 0.000365 | 0.006348 |
GO:0061014 | positive regulation of mRNA catabolic process | 4.08% (4/98) | 3.55 | 0.000393 | 0.006576 |
GO:0035239 | tube morphogenesis | 4.08% (4/98) | 3.55 | 0.000393 | 0.006576 |
GO:0060485 | mesenchyme development | 2.04% (2/98) | 6.05 | 0.000404 | 0.006671 |
GO:0019439 | aromatic compound catabolic process | 8.16% (8/98) | 2.19 | 0.000392 | 0.006737 |
GO:0070995 | NADPH oxidation | 2.04% (2/98) | 5.94 | 0.000477 | 0.007223 |
GO:0045661 | regulation of myoblast differentiation | 2.04% (2/98) | 5.94 | 0.000477 | 0.007223 |
GO:0060298 | positive regulation of sarcomere organization | 2.04% (2/98) | 5.94 | 0.000477 | 0.007223 |
GO:2001014 | regulation of skeletal muscle cell differentiation | 2.04% (2/98) | 5.94 | 0.000477 | 0.007223 |
GO:0043067 | regulation of programmed cell death | 10.2% (10/98) | 1.85 | 0.00046 | 0.007403 |
GO:0004519 | endonuclease activity | 5.1% (5/98) | 2.98 | 0.000454 | 0.007407 |
GO:0031047 | gene silencing by RNA | 5.1% (5/98) | 2.97 | 0.000471 | 0.007487 |
GO:0070401 | NADP+ binding | 2.04% (2/98) | 5.83 | 0.000555 | 0.008219 |
GO:0010327 | acetyl CoA:(Z)-3-hexen-1-ol acetyltransferase activity | 2.04% (2/98) | 5.83 | 0.000555 | 0.008219 |
GO:0004675 | transmembrane receptor protein serine/threonine kinase activity | 4.08% (4/98) | 3.39 | 0.000598 | 0.008749 |
GO:0010629 | negative regulation of gene expression | 9.18% (9/98) | 1.93 | 0.000613 | 0.008871 |
GO:0016730 | oxidoreductase activity, acting on iron-sulfur proteins as donors | 2.04% (2/98) | 5.73 | 0.00064 | 0.009052 |
GO:0047203 | 13-hydroxylupinine O-tigloyltransferase activity | 2.04% (2/98) | 5.73 | 0.00064 | 0.009052 |
GO:1901361 | organic cyclic compound catabolic process | 8.16% (8/98) | 2.06 | 0.000689 | 0.009647 |
GO:0006768 | biotin metabolic process | 2.04% (2/98) | 5.64 | 0.00073 | 0.009689 |
GO:0009102 | biotin biosynthetic process | 2.04% (2/98) | 5.64 | 0.00073 | 0.009689 |
GO:1901787 | benzoyl-CoA metabolic process | 2.04% (2/98) | 5.64 | 0.00073 | 0.009689 |
GO:0048702 | embryonic neurocranium morphogenesis | 2.04% (2/98) | 5.64 | 0.00073 | 0.009689 |
GO:0016893 | endonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5'-phosphomonoesters | 3.06% (3/98) | 4.12 | 0.00071 | 0.009835 |
GO:0036002 | pre-mRNA binding | 3.06% (3/98) | 4.07 | 0.000772 | 0.010144 |
GO:0060297 | regulation of sarcomere organization | 2.04% (2/98) | 5.47 | 0.000927 | 0.012065 |
GO:0042221 | response to chemical | 38.78% (38/98) | 0.67 | 0.001106 | 0.013836 |
GO:0051607 | defense response to virus | 5.1% (5/98) | 2.69 | 0.001098 | 0.013868 |
GO:0140546 | defense response to symbiont | 5.1% (5/98) | 2.69 | 0.001098 | 0.013868 |
GO:0019637 | organophosphate metabolic process | 10.2% (10/98) | 1.68 | 0.001157 | 0.01393 |
GO:0035197 | siRNA binding | 2.04% (2/98) | 5.32 | 0.001148 | 0.013947 |
GO:0048738 | cardiac muscle tissue development | 2.04% (2/98) | 5.32 | 0.001148 | 0.013947 |
GO:0000381 | regulation of alternative mRNA splicing, via spliceosome | 3.06% (3/98) | 3.9 | 0.001092 | 0.01406 |
GO:0010608 | post-transcriptional regulation of gene expression | 8.16% (8/98) | 1.95 | 0.001146 | 0.014188 |
GO:0010050 | vegetative phase change | 2.04% (2/98) | 5.25 | 0.001267 | 0.014566 |
GO:0004525 | ribonuclease III activity | 2.04% (2/98) | 5.25 | 0.001267 | 0.014566 |
GO:0032296 | double-stranded RNA-specific ribonuclease activity | 2.04% (2/98) | 5.25 | 0.001267 | 0.014566 |
GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | 2.04% (2/98) | 5.25 | 0.001267 | 0.014566 |
GO:0010035 | response to inorganic substance | 20.41% (20/98) | 1.05 | 0.001227 | 0.014628 |
GO:0071215 | cellular response to abscisic acid stimulus | 4.08% (4/98) | 3.09 | 0.001291 | 0.014711 |
GO:0001756 | somitogenesis | 2.04% (2/98) | 5.18 | 0.001391 | 0.015313 |
GO:0097157 | pre-mRNA intronic binding | 2.04% (2/98) | 5.18 | 0.001391 | 0.015313 |
GO:0050779 | RNA destabilization | 3.06% (3/98) | 3.78 | 0.001391 | 0.015574 |
GO:0061157 | mRNA destabilization | 3.06% (3/98) | 3.78 | 0.001391 | 0.015574 |
GO:0048522 | positive regulation of cellular process | 25.51% (25/98) | 0.88 | 0.001511 | 0.016491 |
GO:0010830 | regulation of myotube differentiation | 2.04% (2/98) | 5.05 | 0.001657 | 0.01778 |
GO:0061158 | 3'-UTR-mediated mRNA destabilization | 2.04% (2/98) | 5.05 | 0.001657 | 0.01778 |
GO:0016788 | hydrolase activity, acting on ester bonds | 11.22% (11/98) | 1.51 | 0.001708 | 0.018181 |
GO:0000166 | nucleotide binding | 20.41% (20/98) | 1.01 | 0.001817 | 0.01872 |
GO:1901265 | nucleoside phosphate binding | 20.41% (20/98) | 1.01 | 0.001817 | 0.01872 |
GO:0048527 | lateral root development | 5.1% (5/98) | 2.53 | 0.001808 | 0.018928 |
GO:2000738 | positive regulation of stem cell differentiation | 2.04% (2/98) | 5.0 | 0.001798 | 0.018979 |
GO:0051254 | positive regulation of RNA metabolic process | 13.27% (13/98) | 1.33 | 0.001932 | 0.019442 |
GO:0009615 | response to virus | 6.12% (6/98) | 2.22 | 0.001907 | 0.01949 |
GO:0045089 | positive regulation of innate immune response | 6.12% (6/98) | 2.22 | 0.001925 | 0.019525 |
GO:0042048 | olfactory behavior | 2.04% (2/98) | 4.88 | 0.002096 | 0.020771 |
GO:0042303 | molting cycle | 2.04% (2/98) | 4.88 | 0.002096 | 0.020771 |
GO:1903313 | positive regulation of mRNA metabolic process | 4.08% (4/98) | 2.89 | 0.002147 | 0.021113 |
GO:0043531 | ADP binding | 4.08% (4/98) | 2.86 | 0.002295 | 0.022397 |
GO:0004888 | transmembrane signaling receptor activity | 5.1% (5/98) | 2.44 | 0.002363 | 0.02288 |
GO:1990923 | PET complex | 1.02% (1/98) | 8.64 | 0.002507 | 0.023066 |
GO:0042835 | BRE binding | 1.02% (1/98) | 8.64 | 0.002507 | 0.023066 |
GO:0061031 | endodermal digestive tract morphogenesis | 1.02% (1/98) | 8.64 | 0.002507 | 0.023066 |
GO:0061113 | pancreas morphogenesis | 1.02% (1/98) | 8.64 | 0.002507 | 0.023066 |
GO:1990402 | embryonic liver development | 1.02% (1/98) | 8.64 | 0.002507 | 0.023066 |
GO:0048528 | post-embryonic root development | 5.1% (5/98) | 2.43 | 0.002419 | 0.023075 |
GO:2000765 | regulation of cytoplasmic translation | 2.04% (2/98) | 4.78 | 0.002417 | 0.023232 |
GO:0050734 | hydroxycinnamoyltransferase activity | 2.04% (2/98) | 4.73 | 0.002585 | 0.023451 |
GO:0030330 | DNA damage response, signal transduction by p53 class mediator | 2.04% (2/98) | 4.73 | 0.002585 | 0.023451 |
GO:0007635 | chemosensory behavior | 2.04% (2/98) | 4.69 | 0.002759 | 0.02451 |
GO:0014706 | striated muscle tissue development | 2.04% (2/98) | 4.69 | 0.002759 | 0.02451 |
GO:0051155 | positive regulation of striated muscle cell differentiation | 2.04% (2/98) | 4.69 | 0.002759 | 0.02451 |
GO:0120255 | olefinic compound biosynthetic process | 4.08% (4/98) | 2.79 | 0.002781 | 0.024537 |
GO:1901363 | heterocyclic compound binding | 37.76% (37/98) | 0.61 | 0.002891 | 0.025333 |
GO:0061013 | regulation of mRNA catabolic process | 4.08% (4/98) | 2.77 | 0.002913 | 0.025351 |
GO:0110020 | regulation of actomyosin structure organization | 2.04% (2/98) | 4.64 | 0.002938 | 0.0254 |
GO:0097306 | cellular response to alcohol | 4.08% (4/98) | 2.75 | 0.003049 | 0.026006 |
GO:0090696 | post-embryonic plant organ development | 5.1% (5/98) | 2.36 | 0.003032 | 0.026039 |
GO:0051149 | positive regulation of muscle cell differentiation | 2.04% (2/98) | 4.6 | 0.003123 | 0.026119 |
GO:1990825 | sequence-specific mRNA binding | 2.04% (2/98) | 4.6 | 0.003123 | 0.026119 |
GO:0045088 | regulation of innate immune response | 7.14% (7/98) | 1.88 | 0.003091 | 0.026194 |
GO:0038023 | signaling receptor activity | 7.14% (7/98) | 1.87 | 0.003159 | 0.026248 |
GO:0009617 | response to bacterium | 14.29% (14/98) | 1.18 | 0.003296 | 0.02687 |
GO:0097159 | organic cyclic compound binding | 37.76% (37/98) | 0.6 | 0.003278 | 0.026892 |
GO:0004518 | nuclease activity | 5.1% (5/98) | 2.33 | 0.003272 | 0.027013 |
GO:0001947 | heart looping | 2.04% (2/98) | 4.51 | 0.003508 | 0.028062 |
GO:0003143 | embryonic heart tube morphogenesis | 2.04% (2/98) | 4.51 | 0.003508 | 0.028062 |
GO:0035282 | segmentation | 2.04% (2/98) | 4.51 | 0.003508 | 0.028062 |
GO:0003730 | mRNA 3'-UTR binding | 3.06% (3/98) | 3.28 | 0.00372 | 0.02904 |
GO:0007639 | homeostasis of number of meristem cells | 2.04% (2/98) | 4.47 | 0.003708 | 0.029121 |
GO:0015026 | coreceptor activity | 2.04% (2/98) | 4.47 | 0.003708 | 0.029121 |
GO:0031571 | mitotic G1 DNA damage checkpoint signaling | 2.04% (2/98) | 4.47 | 0.003708 | 0.029121 |
GO:0032870 | cellular response to hormone stimulus | 6.12% (6/98) | 2.02 | 0.003763 | 0.029195 |
GO:0045935 | positive regulation of nucleobase-containing compound metabolic process | 13.27% (13/98) | 1.22 | 0.003806 | 0.029355 |
GO:0044819 | mitotic G1/S transition checkpoint signaling | 2.04% (2/98) | 4.43 | 0.003914 | 0.030004 |
GO:0060089 | molecular transducer activity | 7.14% (7/98) | 1.8 | 0.004171 | 0.03179 |
GO:0035925 | mRNA 3'-UTR AU-rich region binding | 2.04% (2/98) | 4.28 | 0.004787 | 0.03627 |
GO:0098795 | global gene silencing by mRNA cleavage | 1.02% (1/98) | 7.64 | 0.005008 | 0.037071 |
GO:0071625 | vocalization behavior | 1.02% (1/98) | 7.64 | 0.005008 | 0.037071 |
GO:0097356 | perinucleolar compartment | 1.02% (1/98) | 7.64 | 0.005008 | 0.037071 |
GO:0099153 | synaptic transmission, serotonergic | 1.02% (1/98) | 7.64 | 0.005008 | 0.037071 |
GO:0019199 | transmembrane receptor protein kinase activity | 4.08% (4/98) | 2.54 | 0.005096 | 0.037504 |
GO:0007389 | pattern specification process | 9.18% (9/98) | 1.47 | 0.005277 | 0.038619 |
GO:0048873 | homeostasis of number of cells within a tissue | 2.04% (2/98) | 4.18 | 0.005496 | 0.039768 |
GO:0002239 | response to oomycetes | 5.1% (5/98) | 2.15 | 0.005494 | 0.039982 |
GO:2000113 | negative regulation of cellular macromolecule biosynthetic process | 4.08% (4/98) | 2.5 | 0.005635 | 0.040547 |
GO:0070696 | transmembrane receptor protein serine/threonine kinase binding | 2.04% (2/98) | 4.15 | 0.005742 | 0.040637 |
GO:0005310 | dicarboxylic acid transmembrane transporter activity | 2.04% (2/98) | 4.15 | 0.005742 | 0.040637 |
GO:0036094 | small molecule binding | 20.41% (20/98) | 0.86 | 0.005686 | 0.040687 |
GO:0008889 | glycerophosphodiester phosphodiesterase activity | 2.04% (2/98) | 4.12 | 0.005993 | 0.042183 |
GO:0009836 | fruit ripening, climacteric | 2.04% (2/98) | 4.0 | 0.007048 | 0.049067 |
GO:0009952 | anterior/posterior pattern specification | 2.04% (2/98) | 4.0 | 0.007048 | 0.049067 |